The Role of C-11 Choline PET in Patients With Prostate Cancer
Launched by CHANG GUNG MEMORIAL HOSPITAL · Jul 28, 2016
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
\[11C\] choline positron emission tomography (PET) is an emerging modality for staging at initial diagnosis or re-staging at the time of treatment failure. The updated study shows 11C -labeled choline derivatives seem to be the most promising PET radionuclides in assessment of prostate cancer and USA FDA approves the utility of C-11 Choline in prostate cancer patients in 2012 September.
To our best literature search, there are only few preliminary studies regarding application of PET/MR in prostate cancer patients and the initial results in correlation of functional MRI and PET images seem...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Clinically suspicious and/or pathology-proved high risk group prostate cancer patients (PSA \> 20 ng/mL, or Gleason score 8-10, or clinical stage \>T2c)
- • 2. Age equals or more than 20 years old
- • 3. Willing to sign the informed consent
- Exclusion Criteria:
- • 1. Patients with a concomitant or previous malignancy history
- • 2. Unable to tolerate MR or PET/CT scan, such as those with magnetic implants (e.g. those received intracranial aneurysm surgery, cardiac pacemaker, artificial valves replacement, artificial ears, hip prosthesis), claustrophobia, unable to lie still
- • 3. Unable to give informed consent
- • 4. Previous allergy to carbon-labelled radionuclide
About Chang Gung Memorial Hospital
Chang Gung Memorial Hospital, one of the largest healthcare organizations in Taiwan, is renowned for its commitment to advancing medical research and improving patient care. As a clinical trial sponsor, the hospital leverages its extensive clinical expertise and state-of-the-art facilities to conduct innovative research across various medical disciplines. With a focus on collaboration and ethical practices, Chang Gung Memorial Hospital aims to contribute to the global body of medical knowledge through rigorous clinical trials that enhance treatment options and improve health outcomes for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials